Aerpio Pharmaceuticals Inc (ARPO) Major Shareholder Sells $122,997.00 in Stock

Aerpio Pharmaceuticals Inc (OTCMKTS:ARPO) major shareholder Bioventures Ltd Novartis sold 117,140 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $1.05, for a total value of $122,997.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Bioventures Ltd Novartis also recently made the following trade(s):

  • On Wednesday, April 10th, Bioventures Ltd Novartis sold 200,746 shares of Aerpio Pharmaceuticals stock. The shares were sold at an average price of $1.07, for a total value of $214,798.22.
  • On Friday, April 5th, Bioventures Ltd Novartis sold 130,594 shares of Aerpio Pharmaceuticals stock. The shares were sold at an average price of $0.99, for a total value of $129,288.06.
  • On Tuesday, April 2nd, Bioventures Ltd Novartis sold 231,763 shares of Aerpio Pharmaceuticals stock. The shares were sold at an average price of $0.94, for a total value of $217,857.22.
  • On Thursday, March 28th, Bioventures Ltd Novartis sold 317,346 shares of Aerpio Pharmaceuticals stock. The shares were sold at an average price of $0.99, for a total value of $314,172.54.

Shares of ARPO opened at $1.01 on Wednesday. Aerpio Pharmaceuticals Inc has a 52-week low of $0.88 and a 52-week high of $4.95.

Aerpio Pharmaceuticals (OTCMKTS:ARPO) last issued its earnings results on Tuesday, March 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03).

A number of brokerages have issued reports on ARPO. Zacks Investment Research raised Aerpio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a research note on Tuesday, April 9th. National Securities downgraded Aerpio Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, March 18th. Cantor Fitzgerald set a $8.00 target price on Aerpio Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, February 11th. Guggenheim downgraded Aerpio Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, March 18th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Aerpio Pharmaceuticals in a research note on Wednesday, March 6th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Aerpio Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $7.65.

Large investors have recently modified their holdings of the stock. HarbourVest Partners LLC acquired a new stake in shares of Aerpio Pharmaceuticals during the 4th quarter worth about $246,000. Vanguard Group Inc. acquired a new stake in shares of Aerpio Pharmaceuticals during the 3rd quarter worth about $3,331,000. Vanguard Group Inc acquired a new stake in shares of Aerpio Pharmaceuticals during the 3rd quarter worth about $3,331,000. Acadian Asset Management LLC acquired a new stake in shares of Aerpio Pharmaceuticals during the 4th quarter worth about $28,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Aerpio Pharmaceuticals during the 4th quarter worth about $36,000. 0.37% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Aerpio Pharmaceuticals Inc (ARPO) Major Shareholder Sells $122,997.00 in Stock” was first reported by Stock Observer and is the property of of Stock Observer. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.thestockobserver.com/2019/04/17/aerpio-pharmaceuticals-inc-arpo-major-shareholder-sells-122997-00-in-stock.html.

Aerpio Pharmaceuticals Company Profile

Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes proprietary therapeutics for treating ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the tie-2 pathway, which completed Phase 2a clinical trials for the treatment of diabetic macular edema.

Further Reading: Marijuana Stocks Investing Considerations

Insider Buying and Selling by Quarter for Aerpio Pharmaceuticals (OTCMKTS:ARPO)

Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.